AMANDA SPEICHER: Open Payments
NPI 1376843011 · NEW LONDON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,900 in 94 payments from 11 companies in 2025. Trend: 2023 $1,310 · 2024 $1,087 · 2025 $1,900
Food & beverage: $1,797Education: $103
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 15 | $281 |
| Teva Pharmaceuticals USA, Inc. | 12 | $278 |
| Otsuka America Pharmaceutical, Inc. | 14 | $270 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $248 |
| ABBVIE INC. | 12 | $223 |
| Vanda Pharmaceuticals Inc. | 9 | $193 |
| Lundbeck LLC | 8 | $152 |
| Alkermes, Inc. | 4 | $93 |
| Axsome Therapeutics, Inc. | 3 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
Products named: REXULTI, INGREZZA, CAPLYTA, VRAYLAR, FANAPT, AUSTEDO XR, ARISTADA, Auvelity.
Industry payments across CT — which companies pay providers there.
